Want to see HK:9886 full AI Analyst Report?
9886 Stock Chart & Stats
HK$1.08
-HK$0.02(-3.23%)
At close: 4:00 PM EST
HK$1.08
-HK$0.02(-3.23%)
Day’s Range― - ―
52-Week RangeHK$0.51 - HK$1.37
Previous CloseN/A
Volume431.00K
Average Volume (3M)4.91M
Market Cap
HK$1.12B
Enterprise ValueHK$845.29M
Total Cash (Recent Filing)HK$1.12B
Total Debt (Recent Filing)HK$281.81M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,240,312,900
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.35
Revenue Forecast (FY)HK$126.42B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin RecoveryA strong 2025 top-line rebound and higher gross margin indicate improving product mix and scale in the O2O pharmacy model. Persistent revenue growth and margin improvement support durable unit economics, better coverage of fixed costs, and a clearer path to sustained profitability if the trend continues.
Positive Free Cash Flow GenerationThe shift to positive operating and free cash flow enhances financial flexibility, enabling reinvestment in delivery and store networks without relying solely on external financing. Durable FCF, if maintained, supports capex, working-capital needs and reduces refinancing risk for the O2O retail model.
Manageable Leverage And Stronger Balance SheetLow leverage and positive equity across recent years provide resilience to revenue variability and room to fund organic expansion. A healthier balance sheet supports supplier relationships, potential strategic investments, and gives time for management to execute on stabilizing margins and cash generation.
Bears Say
Still Slightly UnprofitableAlthough losses narrowed, the company remains slightly unprofitable and ROE is negative, meaning shareholder capital has not been consistently productive. Persistent marginal losses could force dependence on external funding and limit long-term reinvestment unless margins convert to sustained positive net income.
Cash-flow Volatility HistoricallyA one-year swing to positive cash flows after multi-year negatives raises durability concerns; if 2025 FCF benefited from timing or working-capital moves, cash can revert. Unstable cash conversion complicates planning, capital allocation, and reduces confidence that current cash strength is structural.
Past Balance-sheet Stress Indicating Execution RiskHistorical episodes of negative equity and heavy leverage reveal prior execution failures or funding strains. That track record increases the risk that adverse market or operational swings could re-expose weaknesses, meaning management must demonstrate consistent discipline to avoid repeating prior stress.
Dingdang Health Technology Group Ltd. News
9886 FAQ
What was Dingdang Health Technology Group Ltd.’s price range in the past 12 months?
Dingdang Health Technology Group Ltd. lowest stock price was HK$0.51 and its highest was HK$1.37 in the past 12 months.
What is Dingdang Health Technology Group Ltd.’s market cap?
Dingdang Health Technology Group Ltd.’s market cap is HK$1.12B.
When is Dingdang Health Technology Group Ltd.’s upcoming earnings report date?
Dingdang Health Technology Group Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 34 days.
How were Dingdang Health Technology Group Ltd.’s earnings last quarter?
Dingdang Health Technology Group Ltd. released its earnings results on Mar 20, 2026. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Dingdang Health Technology Group Ltd. overvalued?
According to Wall Street analysts Dingdang Health Technology Group Ltd.’s price is currently Overvalued.
Does Dingdang Health Technology Group Ltd. pay dividends?
Dingdang Health Technology Group Ltd. does not currently pay dividends.
What is Dingdang Health Technology Group Ltd.’s EPS estimate?
Dingdang Health Technology Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dingdang Health Technology Group Ltd. have?
Dingdang Health Technology Group Ltd. has 1,240,312,900 shares outstanding.
What happened to Dingdang Health Technology Group Ltd.’s price movement after its last earnings report?
Dingdang Health Technology Group Ltd. reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of Dingdang Health Technology Group Ltd.?
Currently, no hedge funds are holding shares in HK:9886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dingdang Health Technology Group Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
-2.95%
Trailing 12-Months
Asset Growth
12.67%
Trailing 12-Months
Company Description
Dingdang Health Technology Group Ltd.
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―